Elmiron, manufactured by Janssen Pharmaceuticals, was approved to treat a painful bladder condition (interstitial cystitis) in September 1996. Janssen, a subsidiary of Teva Pharmaceuticals and Johnson & Johnson touted the drug as the first and only oral medication to treat bladder pain and interstitial cystitis).
However, in 2018 research began to associate Elmiron (pentosan polysulfate sodium) with potentially vision damage after prolonged use.
Our firm has decades of experience litigating defective drug products and is investigating claims made arising from Elmira vision loss. Contact us today online by filling out the contact form on this page, or by telephone at (212) 684-1880 to speak with a knowledgeable New York defective defective drug attorney.
The Elmiron research found that prolonged use of Elmiron could result in pigmentary maculopathy. Researchers discovered that a type of pigmentary maculopathy was unique to Elmiron use. Those who’ve experienced such difficulty found that they had trouble reading, adjusting to lighter or darker settings, and difficulty seeing objects that are close.
Helping Clients Across the Country
For more information about our legal services, call (212) 684-1880 and speak with one of our experienced trial attorneys
Elmiron is an oral medication used to treat bladder discomfort and interstitial cystitis, primarily found in women. Elmiron is the only FDA-approved pill to treat it. As a mainstay of treatment for decades, hundreds of thousands of people have likely been exposed to the drug.
According to Science Daily, “Nieraj Jain, M.D., of Emory Eye Center in Atlanta, Ga., reported that six patients who had been taking Elmiron for about 15 years had developed unusual changes in their macula, the central part of the retina responsible for delivering clear, crisp, central vison. Because nothing in the patients’ medical history or diagnostic tests explained the subtle, but striking pattern of abnormalities, Dr. Jain and his colleagues raised a warning flag that long-term use of Elmiron may damage the retina.”
Injuries associated with prolonged Elmiron use include pigmentary maculopathy, blurred vision, halo vision, retinopathy, and bilateral or unilateral blindness.
Rheingold Giuffra Ruffo & Plotkin have successfully litigated cases against manufacturers of defective drugs, and are currently speaking with those injured through the use of Elmiron. Our lawyers are investigating Elmiron lawsuits and are speaking with those who have been negatively impacted by Elmiron. Our firm has aggressively represented clients and has recovered over $2 billion in medical malpractice, mass tort, personal injury, defective drugs, and product liability cases. Get started on your case today.
Our team serves victims of defective drugs across the nation. Call (212) 684-1880 to learn more during a free and confidential consultation.